Search results
This edition marks the start of the charity's 50th anniversary year. It includes lots of ways to get involved over the next 12 months along with details of our Annual and Professionals' Conferences in September.
Since the publication of this newsletter our founder and honorary president Lynda Cantor MBE has passed away. We are all deeply saddened by this news.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Inside: Our intrepid Sahara Trek #TeamRetinaUK tell us about their incredible experience. 2026 is now fully underway and we are excited to tell you about our plans. Could you take part in a challenge event or volunteer to do a bucket collection in London for Retina UK?
From our newsletters to the recordings of our webinars and everything in-between, use the filters (below) to find the content that's right for you.
Different inherited sight loss conditions present noticeable symptoms at different times.
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
